Access : A phase I|[sol]|II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer : British Journal of Cancer

Links shared publicly online about this topic.

905
total visits

Access : A phase I|[sol]|II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer : British Journal of Cancer

The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial i

View full resource at nature.com

Tags: Cancer, Kidney Cancer, Renal Cell Carcinoma, Kidney Health, Urinary System